The Experts below are selected from a list of 3891 Experts worldwide ranked by ideXlab platform

Jayne E Edwards - One of the best experts on this subject based on the ideXlab platform.

  • The Cochrane Library - Single dose oral Indometacin for the treatment of acute postoperative pain
    Cochrane Database of Systematic Reviews, 2004
    Co-Authors: R Andrew Moore, Sheena Derry, Lorna Mason, Henry J Mcquay, Jayne E Edwards
    Abstract:

    Background This is an updated version of the original Cochrane review published in Issue 4, 2004. Indometacin is a non-steroidal anti-inflammatory drug (NSAID) used most commonly for the treatment of inflammation and pain resulting from rheumatic disease (arthritis), and less commonly in postoperative pain management. When taken for chronic pain conditions, Indometacin has been associated with a high incidence of adverse events. The benefits and harms of orally-administered Indometacin for postoperative pain are not clear. Objectives To determine the efficacy of a single dose of oral Indometacin compared with placebo in treating acute postoperative pain in adults, and to analyse information relating to adverse events. Search methods We searched the Cochrane CENTRAL Register of Controlled Trials in The Cochrane Library, MEDLINE, EMBASE and the Oxford Pain Relief Database for relevant studies in January 2002 and for the updated search in December 2007. Additional studies were sought from the reference lists of retrieved studies. Selection criteria Studies were included in the review if they were randomised, double blind, placebo-controlled clinical trials using a single oral dose of Indometacin in adults with acute postoperative pain. Data collection and analysis Studies were assessed independently by two review authors. Pain relief or pain intensity data were extracted and converted into dichotomous information to give the number of participants with at least 50% pain relief over four to six hours. The relative benefit for at least 50% pain relief was calculated. Main results In the original review one study of 59 women with post-episiotomy pain met the inclusion criteria. The dose of Indometacin assessed against placebo was 50 mg, and the results concluded that Indometacin was not significantly better than placebo for relieving postoperative pain at four to six hours. There was insufficient information to conduct further efficacy analyses or assess adverse events. No further studies were identified in the update of this review. Authors' conclusions Conclusions about the clinical efficacy of Indometacin for postoperative pain cannot be made unless more studies are conducted for a variety of surgical procedures, and different doses of Indometacin are assessed. Since the last version of this review no new relevant studies have been identified.

  • single dose oral Indometacin for the treatment of acute postoperative pain
    Cochrane Database of Systematic Reviews, 2004
    Co-Authors: Andrew R Moore, Sheena Derry, Lorna Mason, Henry J Mcquay, Jayne E Edwards
    Abstract:

    Background This is an updated version of the original Cochrane review published in Issue 4, 2004. Indometacin is a non-steroidal anti-inflammatory drug (NSAID) used most commonly for the treatment of inflammation and pain resulting from rheumatic disease (arthritis), and less commonly in postoperative pain management. When taken for chronic pain conditions, Indometacin has been associated with a high incidence of adverse events. The benefits and harms of orally-administered Indometacin for postoperative pain are not clear. Objectives To determine the efficacy of a single dose of oral Indometacin compared with placebo in treating acute postoperative pain in adults, and to analyse information relating to adverse events. Search methods We searched the Cochrane CENTRAL Register of Controlled Trials in The Cochrane Library, MEDLINE, EMBASE and the Oxford Pain Relief Database for relevant studies in January 2002 and for the updated search in December 2007. Additional studies were sought from the reference lists of retrieved studies. Selection criteria Studies were included in the review if they were randomised, double blind, placebo-controlled clinical trials using a single oral dose of Indometacin in adults with acute postoperative pain. Data collection and analysis Studies were assessed independently by two review authors. Pain relief or pain intensity data were extracted and converted into dichotomous information to give the number of participants with at least 50% pain relief over four to six hours. The relative benefit for at least 50% pain relief was calculated. Main results In the original review one study of 59 women with post-episiotomy pain met the inclusion criteria. The dose of Indometacin assessed against placebo was 50 mg, and the results concluded that Indometacin was not significantly better than placebo for relieving postoperative pain at four to six hours. There was insufficient information to conduct further efficacy analyses or assess adverse events. No further studies were identified in the update of this review. Authors' conclusions Conclusions about the clinical efficacy of Indometacin for postoperative pain cannot be made unless more studies are conducted for a variety of surgical procedures, and different doses of Indometacin are assessed. Since the last version of this review no new relevant studies have been identified.

Andrew R Moore - One of the best experts on this subject based on the ideXlab platform.

  • single dose oral Indometacin for the treatment of acute postoperative pain
    Cochrane Database of Systematic Reviews, 2004
    Co-Authors: Andrew R Moore, Sheena Derry, Lorna Mason, Henry J Mcquay, Jayne E Edwards
    Abstract:

    Background This is an updated version of the original Cochrane review published in Issue 4, 2004. Indometacin is a non-steroidal anti-inflammatory drug (NSAID) used most commonly for the treatment of inflammation and pain resulting from rheumatic disease (arthritis), and less commonly in postoperative pain management. When taken for chronic pain conditions, Indometacin has been associated with a high incidence of adverse events. The benefits and harms of orally-administered Indometacin for postoperative pain are not clear. Objectives To determine the efficacy of a single dose of oral Indometacin compared with placebo in treating acute postoperative pain in adults, and to analyse information relating to adverse events. Search methods We searched the Cochrane CENTRAL Register of Controlled Trials in The Cochrane Library, MEDLINE, EMBASE and the Oxford Pain Relief Database for relevant studies in January 2002 and for the updated search in December 2007. Additional studies were sought from the reference lists of retrieved studies. Selection criteria Studies were included in the review if they were randomised, double blind, placebo-controlled clinical trials using a single oral dose of Indometacin in adults with acute postoperative pain. Data collection and analysis Studies were assessed independently by two review authors. Pain relief or pain intensity data were extracted and converted into dichotomous information to give the number of participants with at least 50% pain relief over four to six hours. The relative benefit for at least 50% pain relief was calculated. Main results In the original review one study of 59 women with post-episiotomy pain met the inclusion criteria. The dose of Indometacin assessed against placebo was 50 mg, and the results concluded that Indometacin was not significantly better than placebo for relieving postoperative pain at four to six hours. There was insufficient information to conduct further efficacy analyses or assess adverse events. No further studies were identified in the update of this review. Authors' conclusions Conclusions about the clinical efficacy of Indometacin for postoperative pain cannot be made unless more studies are conducted for a variety of surgical procedures, and different doses of Indometacin are assessed. Since the last version of this review no new relevant studies have been identified.

Shunsei Hirohata - One of the best experts on this subject based on the ideXlab platform.

  • interaction of Indometacin farnesil a new nonsteroidal antiinflammatory drug with peripheral blood mononuclear cells from patients with rheumatoid arthritis
    Japanese Journal of Clinical Immunology, 1996
    Co-Authors: Shunsei Hirohata, Kinuko Konuma, Tetsufumi Inoue, Koji Ito
    Abstract:

    Indometacin farnesil (Indo-F) is a prodrug of indomethacin designed to reduce the occurrence of side-effects by esterification of the carboxyl group on indomethacin with farnesol. We have examined the pharmacological kinetics and action of Indo-F in peripheral blood mononuclear cells (PBMNC) and polymorphonuclear leukocytes (PBPNL) from patients with rheumatoid arthritis (RA). PBMNC and PBPNL were obtained from 31 RA patients. Indo-F was incubated with PBMNC or PBPNL in the presence or absence of granulocyte-macrophage colony stimulating factor (GM-CSF) (100 pg/ml) for 3 approximately 7 days, after which the concentrations of Indo-F and indomethacin in the culture supernatants or in the cytoplasm extracts were measured with HPLC. The levels of Indo-F in the culture supernatants were significantly decreased in the presence of PBMNC or PBPNL from either normal individuals or RA patients. Indo-F was found to be taken up by PBMNC as well as by PBPNL from RA patients. Conversion of Indo-F into indomethacin was significantly enhanced by GMCSF in the presence of PBMNC, but not PBPNL. The results indicate that Indo-F is taken up by peripheral blood leukocytes from RA patients. Moreover, the data suggest that monocyte-lineage cells might play an important role in the conversion of Indo-F into indomethacin since GM-CSF markedly facilitated the conversion in the presence of PBMNC, but not PBPNL.

Lorna Mason - One of the best experts on this subject based on the ideXlab platform.

  • The Cochrane Library - Single dose oral Indometacin for the treatment of acute postoperative pain
    Cochrane Database of Systematic Reviews, 2004
    Co-Authors: R Andrew Moore, Sheena Derry, Lorna Mason, Henry J Mcquay, Jayne E Edwards
    Abstract:

    Background This is an updated version of the original Cochrane review published in Issue 4, 2004. Indometacin is a non-steroidal anti-inflammatory drug (NSAID) used most commonly for the treatment of inflammation and pain resulting from rheumatic disease (arthritis), and less commonly in postoperative pain management. When taken for chronic pain conditions, Indometacin has been associated with a high incidence of adverse events. The benefits and harms of orally-administered Indometacin for postoperative pain are not clear. Objectives To determine the efficacy of a single dose of oral Indometacin compared with placebo in treating acute postoperative pain in adults, and to analyse information relating to adverse events. Search methods We searched the Cochrane CENTRAL Register of Controlled Trials in The Cochrane Library, MEDLINE, EMBASE and the Oxford Pain Relief Database for relevant studies in January 2002 and for the updated search in December 2007. Additional studies were sought from the reference lists of retrieved studies. Selection criteria Studies were included in the review if they were randomised, double blind, placebo-controlled clinical trials using a single oral dose of Indometacin in adults with acute postoperative pain. Data collection and analysis Studies were assessed independently by two review authors. Pain relief or pain intensity data were extracted and converted into dichotomous information to give the number of participants with at least 50% pain relief over four to six hours. The relative benefit for at least 50% pain relief was calculated. Main results In the original review one study of 59 women with post-episiotomy pain met the inclusion criteria. The dose of Indometacin assessed against placebo was 50 mg, and the results concluded that Indometacin was not significantly better than placebo for relieving postoperative pain at four to six hours. There was insufficient information to conduct further efficacy analyses or assess adverse events. No further studies were identified in the update of this review. Authors' conclusions Conclusions about the clinical efficacy of Indometacin for postoperative pain cannot be made unless more studies are conducted for a variety of surgical procedures, and different doses of Indometacin are assessed. Since the last version of this review no new relevant studies have been identified.

  • single dose oral Indometacin for the treatment of acute postoperative pain
    Cochrane Database of Systematic Reviews, 2004
    Co-Authors: Andrew R Moore, Sheena Derry, Lorna Mason, Henry J Mcquay, Jayne E Edwards
    Abstract:

    Background This is an updated version of the original Cochrane review published in Issue 4, 2004. Indometacin is a non-steroidal anti-inflammatory drug (NSAID) used most commonly for the treatment of inflammation and pain resulting from rheumatic disease (arthritis), and less commonly in postoperative pain management. When taken for chronic pain conditions, Indometacin has been associated with a high incidence of adverse events. The benefits and harms of orally-administered Indometacin for postoperative pain are not clear. Objectives To determine the efficacy of a single dose of oral Indometacin compared with placebo in treating acute postoperative pain in adults, and to analyse information relating to adverse events. Search methods We searched the Cochrane CENTRAL Register of Controlled Trials in The Cochrane Library, MEDLINE, EMBASE and the Oxford Pain Relief Database for relevant studies in January 2002 and for the updated search in December 2007. Additional studies were sought from the reference lists of retrieved studies. Selection criteria Studies were included in the review if they were randomised, double blind, placebo-controlled clinical trials using a single oral dose of Indometacin in adults with acute postoperative pain. Data collection and analysis Studies were assessed independently by two review authors. Pain relief or pain intensity data were extracted and converted into dichotomous information to give the number of participants with at least 50% pain relief over four to six hours. The relative benefit for at least 50% pain relief was calculated. Main results In the original review one study of 59 women with post-episiotomy pain met the inclusion criteria. The dose of Indometacin assessed against placebo was 50 mg, and the results concluded that Indometacin was not significantly better than placebo for relieving postoperative pain at four to six hours. There was insufficient information to conduct further efficacy analyses or assess adverse events. No further studies were identified in the update of this review. Authors' conclusions Conclusions about the clinical efficacy of Indometacin for postoperative pain cannot be made unless more studies are conducted for a variety of surgical procedures, and different doses of Indometacin are assessed. Since the last version of this review no new relevant studies have been identified.

Sheena Derry - One of the best experts on this subject based on the ideXlab platform.

  • The Cochrane Library - Single dose oral Indometacin for the treatment of acute postoperative pain
    Cochrane Database of Systematic Reviews, 2004
    Co-Authors: R Andrew Moore, Sheena Derry, Lorna Mason, Henry J Mcquay, Jayne E Edwards
    Abstract:

    Background This is an updated version of the original Cochrane review published in Issue 4, 2004. Indometacin is a non-steroidal anti-inflammatory drug (NSAID) used most commonly for the treatment of inflammation and pain resulting from rheumatic disease (arthritis), and less commonly in postoperative pain management. When taken for chronic pain conditions, Indometacin has been associated with a high incidence of adverse events. The benefits and harms of orally-administered Indometacin for postoperative pain are not clear. Objectives To determine the efficacy of a single dose of oral Indometacin compared with placebo in treating acute postoperative pain in adults, and to analyse information relating to adverse events. Search methods We searched the Cochrane CENTRAL Register of Controlled Trials in The Cochrane Library, MEDLINE, EMBASE and the Oxford Pain Relief Database for relevant studies in January 2002 and for the updated search in December 2007. Additional studies were sought from the reference lists of retrieved studies. Selection criteria Studies were included in the review if they were randomised, double blind, placebo-controlled clinical trials using a single oral dose of Indometacin in adults with acute postoperative pain. Data collection and analysis Studies were assessed independently by two review authors. Pain relief or pain intensity data were extracted and converted into dichotomous information to give the number of participants with at least 50% pain relief over four to six hours. The relative benefit for at least 50% pain relief was calculated. Main results In the original review one study of 59 women with post-episiotomy pain met the inclusion criteria. The dose of Indometacin assessed against placebo was 50 mg, and the results concluded that Indometacin was not significantly better than placebo for relieving postoperative pain at four to six hours. There was insufficient information to conduct further efficacy analyses or assess adverse events. No further studies were identified in the update of this review. Authors' conclusions Conclusions about the clinical efficacy of Indometacin for postoperative pain cannot be made unless more studies are conducted for a variety of surgical procedures, and different doses of Indometacin are assessed. Since the last version of this review no new relevant studies have been identified.

  • single dose oral Indometacin for the treatment of acute postoperative pain
    Cochrane Database of Systematic Reviews, 2004
    Co-Authors: Andrew R Moore, Sheena Derry, Lorna Mason, Henry J Mcquay, Jayne E Edwards
    Abstract:

    Background This is an updated version of the original Cochrane review published in Issue 4, 2004. Indometacin is a non-steroidal anti-inflammatory drug (NSAID) used most commonly for the treatment of inflammation and pain resulting from rheumatic disease (arthritis), and less commonly in postoperative pain management. When taken for chronic pain conditions, Indometacin has been associated with a high incidence of adverse events. The benefits and harms of orally-administered Indometacin for postoperative pain are not clear. Objectives To determine the efficacy of a single dose of oral Indometacin compared with placebo in treating acute postoperative pain in adults, and to analyse information relating to adverse events. Search methods We searched the Cochrane CENTRAL Register of Controlled Trials in The Cochrane Library, MEDLINE, EMBASE and the Oxford Pain Relief Database for relevant studies in January 2002 and for the updated search in December 2007. Additional studies were sought from the reference lists of retrieved studies. Selection criteria Studies were included in the review if they were randomised, double blind, placebo-controlled clinical trials using a single oral dose of Indometacin in adults with acute postoperative pain. Data collection and analysis Studies were assessed independently by two review authors. Pain relief or pain intensity data were extracted and converted into dichotomous information to give the number of participants with at least 50% pain relief over four to six hours. The relative benefit for at least 50% pain relief was calculated. Main results In the original review one study of 59 women with post-episiotomy pain met the inclusion criteria. The dose of Indometacin assessed against placebo was 50 mg, and the results concluded that Indometacin was not significantly better than placebo for relieving postoperative pain at four to six hours. There was insufficient information to conduct further efficacy analyses or assess adverse events. No further studies were identified in the update of this review. Authors' conclusions Conclusions about the clinical efficacy of Indometacin for postoperative pain cannot be made unless more studies are conducted for a variety of surgical procedures, and different doses of Indometacin are assessed. Since the last version of this review no new relevant studies have been identified.